
An experimental antibiotic that targets antibiotic-resistant ‘superbugs’ has proved to be safe and well tolerated in a Phase 1 clinical trial.
The new drug, QPX9003, was developed by Monash University researchers – and offers some real hope to holding off a predicted ‘superbug’ catastrophe.